As we head into Cannabis Europa, Business of Cannabis chats with Sasho Stefanoski, CEO of PHCANN International.
Sasho, what do you see as the most significant developments shaping the European cannabis industry right now?
Europe is entering a very defining moment because the industry is starting to develop its own identity rather than simply following models imported from elsewhere.
For several years, much of the global cannabis conversation was dominated by expansion speed, valuation growth, and volume. Europe is now moving in a different direction. The market is becoming more measured, more medically oriented, and far more focused on long-term sustainability.
What is particularly interesting right now is the collision between pharmaceutical discipline and modern cannabis culture. Patients are becoming more educated, physicians are becoming more comfortable, and companies are beginning to understand that success in Europe will not come from copying North American models directly. Europe requires a different balance — one built around regulation, trust, product consistency, and healthcare integration.
At the same time, we are seeing increasing fragmentation in the market. Some operators are competing almost entirely on price, while others are investing into quality, branding, genetics, and long-term positioning. I believe that divide will become even more visible over the next 24 months.
Another major development is that patients themselves are evolving faster than the industry expected. They are becoming far more sophisticated in how they understand cultivars, terpene expression, product quality, and treatment experience. That changes the entire dynamic of the market.
Ultimately, I believe Europe is slowly building a cannabis industry that looks more like a long-term healthcare ecosystem and less like a speculative commodity cycle. That transition may be slower, but in the long run it creates stronger foundations.
When we last spoke Sasho, you related how PHCANN had moved ‘from building belief to building trust.’ A year on, has that transition materialised across the European market – or are there markets where hype still hasn’t given way to discipline?
I think the industry today is somewhere between those two worlds.
The belief phase is clearly behind us. Nobody serious is questioning anymore whether medical cannabis has a future in Europe. The discussion now is about who can actually execute consistently in a very demanding environment.
But trust is still unevenly distributed across the industry.
What we are seeing now is a kind of natural separation process. Companies that were built around infrastructure, compliance, and long-term operational thinking are becoming more resilient. Others that relied mainly on momentum or aggressive expansion are finding the current market conditions much more difficult.
What is interesting is that trust today is no longer built only through certifications or scale. It is built through consistency of execution. Can you supply reliably? Can you maintain standards under pressure? Can you create products that physicians feel confident prescribing repeatedly? Can patients depend on product consistency month after month?
Those questions are becoming much more important than pure growth narratives.
I also think the European market is becoming emotionally more mature. A few years ago, the industry was driven heavily by excitement. Today, there is more realism, more discipline, and in many ways more professionalism.
That is healthy for the long-term future of the sector.
PHCANN Exotics has launched in Germany and the UK. What has the early market response told you about where European prescribers and patients actually are on product sophistication?
The response surprised even us in certain ways because it showed how quickly the European patient base is evolving.
There is now a much deeper understanding of cannabis beyond simple potency metrics. Patients are increasingly discussing terpene complexity, cultivar character, flavour profiles, production quality, moisture balance, curing standards, and overall experience consistency.
That tells us something very important: Europe is moving from a transactional cannabis market toward a more experience-aware medical market.
At the same time, patients still expect pharmaceutical reliability. That combination is what makes Europe unique. The market wants products with identity and sophistication, but it also expects safety, predictability, and medical consistency.
I think this is where the future of premium medical cannabis will evolve.
For many years, the industry treated “medical” and “premium cannabis culture” almost as separate worlds. What we are seeing now is the beginning of those worlds merging. Patients do not want low-quality medical products simply because they are compliant. They increasingly expect medical products to also deliver a refined and differentiated experience.
That is one of the philosophies behind PHCANN Exotics — bringing premium genetics and modern cannabis sophistication into a highly controlled pharmaceutical framework.
And honestly, I believe Europe may become one of the most sophisticated medical cannabis markets globally over the next decade because of this dynamic.
Price compression is hitting European cannabis markets hard. For a company that has staked its positioning on pharmaceutical quality and premium product, how are you navigating that pressure without diluting what you have built?
Price compression is forcing the industry to become much more honest about its business models.
For a long time, many companies operated in an environment where growth itself could hide inefficiencies. That period is ending. The current market requires operational intelligence, discipline, and clarity of positioning.
Our approach has been very deliberate: we do not want to become trapped in a race to the bottom. In healthcare markets, extreme commoditisation eventually damages trust, quality, and long-term sustainability.
Instead, we focus on creating value through differentiation.
That means investing into genetics, branding, consistency, pharmaceutical standards, operational efficiency, and strategic market positioning rather than relying only on aggressive pricing.
At the same time, we are realistic. The market today requires smarter supply chain structures, more efficient sourcing models, tighter inventory management, and stronger vertical integration. Companies must adapt operationally while protecting the integrity of what they have built.
I also believe premiumisation will continue to exist even during price compression. In every mature industry — whether wine, coffee, pharmaceuticals, or luxury goods — there is always a segment of the market that values consistency, trust, and quality over simply choosing the cheapest option.
Medical cannabis is beginning to evolve in the same direction.
And in many ways, the current pressure may actually accelerate the professionalisation of the sector because it forces companies to define who they truly are and what they genuinely stand for long term.
The post Voices of Cannabis Europa: Sasho Stefanoski, CEO of PHCANN International appeared first on Business of Cannabis.
Continue reading...
Sasho, what do you see as the most significant developments shaping the European cannabis industry right now?
Europe is entering a very defining moment because the industry is starting to develop its own identity rather than simply following models imported from elsewhere.
For several years, much of the global cannabis conversation was dominated by expansion speed, valuation growth, and volume. Europe is now moving in a different direction. The market is becoming more measured, more medically oriented, and far more focused on long-term sustainability.
What is particularly interesting right now is the collision between pharmaceutical discipline and modern cannabis culture. Patients are becoming more educated, physicians are becoming more comfortable, and companies are beginning to understand that success in Europe will not come from copying North American models directly. Europe requires a different balance — one built around regulation, trust, product consistency, and healthcare integration.
At the same time, we are seeing increasing fragmentation in the market. Some operators are competing almost entirely on price, while others are investing into quality, branding, genetics, and long-term positioning. I believe that divide will become even more visible over the next 24 months.
Another major development is that patients themselves are evolving faster than the industry expected. They are becoming far more sophisticated in how they understand cultivars, terpene expression, product quality, and treatment experience. That changes the entire dynamic of the market.
Ultimately, I believe Europe is slowly building a cannabis industry that looks more like a long-term healthcare ecosystem and less like a speculative commodity cycle. That transition may be slower, but in the long run it creates stronger foundations.
When we last spoke Sasho, you related how PHCANN had moved ‘from building belief to building trust.’ A year on, has that transition materialised across the European market – or are there markets where hype still hasn’t given way to discipline?
I think the industry today is somewhere between those two worlds.
The belief phase is clearly behind us. Nobody serious is questioning anymore whether medical cannabis has a future in Europe. The discussion now is about who can actually execute consistently in a very demanding environment.
But trust is still unevenly distributed across the industry.
What we are seeing now is a kind of natural separation process. Companies that were built around infrastructure, compliance, and long-term operational thinking are becoming more resilient. Others that relied mainly on momentum or aggressive expansion are finding the current market conditions much more difficult.
What is interesting is that trust today is no longer built only through certifications or scale. It is built through consistency of execution. Can you supply reliably? Can you maintain standards under pressure? Can you create products that physicians feel confident prescribing repeatedly? Can patients depend on product consistency month after month?
Those questions are becoming much more important than pure growth narratives.
I also think the European market is becoming emotionally more mature. A few years ago, the industry was driven heavily by excitement. Today, there is more realism, more discipline, and in many ways more professionalism.
That is healthy for the long-term future of the sector.
PHCANN Exotics has launched in Germany and the UK. What has the early market response told you about where European prescribers and patients actually are on product sophistication?
The response surprised even us in certain ways because it showed how quickly the European patient base is evolving.
There is now a much deeper understanding of cannabis beyond simple potency metrics. Patients are increasingly discussing terpene complexity, cultivar character, flavour profiles, production quality, moisture balance, curing standards, and overall experience consistency.
That tells us something very important: Europe is moving from a transactional cannabis market toward a more experience-aware medical market.
At the same time, patients still expect pharmaceutical reliability. That combination is what makes Europe unique. The market wants products with identity and sophistication, but it also expects safety, predictability, and medical consistency.
I think this is where the future of premium medical cannabis will evolve.
For many years, the industry treated “medical” and “premium cannabis culture” almost as separate worlds. What we are seeing now is the beginning of those worlds merging. Patients do not want low-quality medical products simply because they are compliant. They increasingly expect medical products to also deliver a refined and differentiated experience.
That is one of the philosophies behind PHCANN Exotics — bringing premium genetics and modern cannabis sophistication into a highly controlled pharmaceutical framework.
And honestly, I believe Europe may become one of the most sophisticated medical cannabis markets globally over the next decade because of this dynamic.
Price compression is hitting European cannabis markets hard. For a company that has staked its positioning on pharmaceutical quality and premium product, how are you navigating that pressure without diluting what you have built?
Price compression is forcing the industry to become much more honest about its business models.
For a long time, many companies operated in an environment where growth itself could hide inefficiencies. That period is ending. The current market requires operational intelligence, discipline, and clarity of positioning.
Our approach has been very deliberate: we do not want to become trapped in a race to the bottom. In healthcare markets, extreme commoditisation eventually damages trust, quality, and long-term sustainability.
Instead, we focus on creating value through differentiation.
That means investing into genetics, branding, consistency, pharmaceutical standards, operational efficiency, and strategic market positioning rather than relying only on aggressive pricing.
At the same time, we are realistic. The market today requires smarter supply chain structures, more efficient sourcing models, tighter inventory management, and stronger vertical integration. Companies must adapt operationally while protecting the integrity of what they have built.
I also believe premiumisation will continue to exist even during price compression. In every mature industry — whether wine, coffee, pharmaceuticals, or luxury goods — there is always a segment of the market that values consistency, trust, and quality over simply choosing the cheapest option.
Medical cannabis is beginning to evolve in the same direction.
And in many ways, the current pressure may actually accelerate the professionalisation of the sector because it forces companies to define who they truly are and what they genuinely stand for long term.
The post Voices of Cannabis Europa: Sasho Stefanoski, CEO of PHCANN International appeared first on Business of Cannabis.
Continue reading...
